Genenta Science (NASDAQ: GNTA) regains Nasdaq minimum bid price compliance
Rhea-AI Filing Summary
Genenta Science S.p.A. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share for continued listing.
Nasdaq notified Genenta on April 10, 2026 that the closing bid price of its American Depositary Shares had been below $1.00 per share for 30 consecutive business days, placing the company out of compliance. Nasdaq has now determined that from June 1, 2026 through June 12, 2026, the closing bid price was at or above $1.00 per share for 10 consecutive business days, restoring compliance and closing the matter.
Positive
- Nasdaq compliance regained: Genenta restored compliance with Nasdaq Listing Rule 5550(a)(2) after its ADSs traded at or above $1.00 for 10 consecutive business days, removing an active minimum bid price deficiency.
Negative
- None.
Insights
Genenta removes an immediate Nasdaq delisting risk by restoring bid-price compliance.
Genenta Science regained compliance with Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares closed at or above $1.00 for 10 consecutive business days from June 1–12, 2026. This resolves the earlier deficiency notice tied to a 30-day period below the threshold.
Maintaining Nasdaq listing status is important for trading liquidity and institutional access, so resolving a bid-price issue can be meaningful for shareholders. Actual long‑term impact will depend on whether the share price remains above the $1.00 minimum in future periods.